Recently, SINOPEG's self-developed products, mPEG-DTA-1 and HO-PEG-DTA-5, have been formally granted European patents! This marks the recognition of domestically produced high-end LNP excipients by the international regulatory system, laying a solid foundation for China's innovative drugs to enter the global market!
As core components of the LNP delivery system, the structure of PEG lipids decisively influences the safety, stability, and immunogenicity of the formulation. SINOPEG has always been committed to the research and development of new technologies and products, and has already secured a significant position in the field of domestic PEG lipid R&D. The newly authorized mPEG-DTA-1 and HO-PEG-DTA-5 are important achievements of the company's continuous innovation in the PEG lipid field.
Innovation Breakthrough: mPEG-DTA-1 and HO-PEG-DTA-5 Granted European Patents
HO-PEG-DTA-5 is a PEG lipid containing a hydroxyl terminal, which, together with its structural counterpart mPEG-DTA-1, forms the core layout of SINOPEG's product series in this category. To date, these two products have completed their global intellectual property layout: they obtained Chinese patent authorization back in 2023 (Patent No.: ZL202280003648.7) and recently received European patent authorization.
(Screenshot source: European Patent Office, Link: https://register.epo.org/application?number=EP22784092&tab=main)
Meanwhile, the independently developed mPEG-DTA-1 has already completed its filing with the CDE (Filing No.: F20230000444) and DMF submission (Filing No.: 039451). Even more encouragingly, HO-PEG-DTA-5 will soon complete dual submissions in China and the US, providing strong excipient support and registration convenience for Chinese innovative pharmaceutical companies aiming for the international mainstream pharmaceutical market!
Note: For more product filing information, please feel free to contact us.
LNP Technology: A Revolutionary Nano-Delivery Platform
Lipid Nanoparticles (LNP), as one of the most successful nano-delivery carriers, have demonstrated exceptional capabilities in delivering cytotoxic chemotherapeutic drugs, antibiotics, and nucleic acid therapeutics. In recent years, with the rapid development of mRNA vaccines and drugs, the importance of LNP technology has become increasingly prominent, making it a focal point in the global pharmaceutical field. The granting of European patents for SINOPEG's products not only reflects the international intellectual property system's recognition of China's innovative achievements but also signifies that Chinese companies are steadily moving towards the center stage in the field of high-end pharmaceutical raw materials, potentially injecting new vitality into the global development of LNP technology.
Product Portfolio: Extensive Layout Meets Diverse Needs
Leveraging profound technical expertise, SINOPEG has developed a variety of novel PEG-lipid structures, providing more high-quality options for global pharmaceutical R&D. The company recently has multiple novel lipid structures readily available to meet different R&D and production needs, including: DSPE-PEG-MAL, GaINAC-PEG-C-DSG, OL-56 (HO-PEG-Ste), mPEG-C16-ceramide, mPEG-DHE-, Biotin-PEG-DMG, DMG-PEG-MAL, HO-PEG-VE, DMG-PEG-Mannose, DSPE-PEG-Galnac, mPEG-DPPE(14:0 PEG2000), mPEG-DMPE(16:0 PEG2000 PE-2K), mPEG-DOPE(18:1 PEG2000 PE-2K).
Looking ahead, SINOPEG will continue to focus on the continuous innovation and breakthrough of core technologies, playing an increasingly important role in the global industrial chain, and contributing Chinese wisdom and strength to the world's public health cause.
Global Contacts
US Tel: +1-844-782-5734
US Tel: +1-844-QUAL-PEG
CHN Tel: +86-400-918-9898
QQ: 1901848004
WeChat: TheLittlePEGGirl
